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Abstract
Background: The DNA alkylating agent temozolomide (TMZ) is widely used in the treatment of human malignancies such as
glioma and melanoma. On the basis of previous structure-activity studies, we recently synthesized a new TMZ selenium
analog by rationally introducing an N-ethylselenocyanate extension to the amide functionality in TMZ structure.
Principal Findings: This TMZ-Se analog showed a superior cytotoxicity to TMZ in human glioma and melanoma cells and
a more potent tumor-inhibiting activity than TMZ in mouse glioma and melanoma xenograft model. TMZ-Se was also
effective against a TMZ-resistant glioma cell line. To explore the mechanism underlying the superior antitumor activity of
TMZ-Se, we compared the effects of TMZ and TMZ-Se on apoptosis and autophagy. Apoptosis was significantly increased in
tumor cells treated with TMZ-Se in comparison to those treated with TMZ. TMZ-Se also triggered greater autophagic
response, as compared with TMZ, and suppressing autophagy partly rescued cell death induced by TMZ-Se, indicating that
TMZ-Se-triggered autophagy contributed to cell death. Although mRNA level of the key autophagy gene, Beclin 1, was
increased, Beclin 1 protein was down-regulated in the cells treated with TMZ-Se. The decrease in Beclin 1 following TMZ-Se
treatment were rescued by the calpain inhibitors and the calpain-mediated degradation of Beclin1 had no effect on
autophagy but promoted apoptosis in cells treated with TMZ-Se.
Conclusions: Our study indicates that incorporation of Se into TMZ can render greater potency to this chemotherapeutic
drug.
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Introduction
TMZ is an oral DNA alkylating agent currently used as an
upfront treatment for glioblastoma multiforme, the most common
and aggressive type of primary brain tumor in human. This
chemotherapeutic agent is also utilized for treating patients with
metastatic melanoma; in particular, due to its ability to penetrate
through the blood-brain barrier, TMZ is often prescribed to
patients with brain metastases of melanoma [1]. This drug exerts
its antitumor activity by interfering with DNA replication. TMZ
can methylate DNA leading to formation of O
6-methylguanine,
the most potent cell-killing lesion, which mispairs with thymine
during the next cycle of DNA replication. Subsequent futile cell
cycles of DNA mismatch result in DNA double strand breaks
(DSBs) and trigger cell death [2]. Although TMZ can improve
overall survival of patients with cancer, the therapeutic outcomes
of this therapy remain unsatisfactory. For instance, nearly 3/4 of
the TMZ-treated glioma patients still die within 2 years, and as
many as 50% of brain tumors are TMZ-resistant. Thus,
developing more effective anticancer drugs would help improve
the outcome of treatment of the malignancies such as glioblastoma
multiforme and melanoma.
The rationale for introducing selenium into the molecule is that
the tredox-active trace element, selenium, is an essential micro-
nutrient and a normal component of diets with chemopreventive
and anticancer properties [3]. Various forms of selenium
compounds have been shown to possess apoptosis-inducing and
anti-proliferative effects, and are thus considered as potential
chemopreventive and chemotherapeutic agents for cancer [4,5,6].
In this study, we tested whether incorporating selenium into TMZ
would improve the anticancer properties of this drug. TMZ
exhibits its anticancer effects by rapid chemical conversion in the
systemic circulation at physiological pH to the active compound
monomethyl triazeno imidazole carboxamide (MTIC), which
further degrades to amino imidazole carboxamide (AIC). The
optimization of the TMZ structure was therefore performed in
such a way as not to hinder this mechanism, which apparently is
responsible for 100% bioavailability of TMZ. We synthesized
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N-ethylselenocyanate extension to the amide functionality known
to be uninvolved in TMZ metabolism, which is responsible for its
activity, thus creating an agent that should contain the properties
of both TMZ and selenium. The chemical structure of TMZ-Se is
shown in Fig. 1. Our results show that TMZ-Se not only showed
superior cytotoxicity to TMZ in human glioma and melanoma
cells, but also was effective against TMZ-resistant tumor cells. In
mouse melanoma and glioma xenograft models, TMZ-Se also
demonstrated stronger anti-tumor activity. The greater cytotoxic-
ity of TMZ-Se may be attributed to its stronger inducing effects on
DSBs, apoptosis and autophagy.
Results
Introduction of Selenium into TMZ Produces Superior
Cytotoxicity to TMZ in Human Glioma and Melanoma
Cells
To determine whether our newly developed TMZ/selenium
derivative, TMZ-Se, had better activity than TMZ in killing tumor
cells, we compared the cytotoxicity of TMZ and TMZ-Se in four
human glioma cell lines T98G, LN229, U251 and U87MG.
Fig. 2A shows that TMZ-Se had a greater inhibitory effect on
proliferation of the tumor cells than TMZ, as determined by cell
viability assay. Colonogenic assay also demonstrated the superior
cytotoxicity of TMZ-Se to TMZ in glioma cells (Fig. 2B).
Additionally, TMZ-Se showed efficacy in inhibiting cell pro-
liferation in a TMZ-resistant human glioma cell line, CCF-STTG
(Fig. 2C). Similar greater cytotoxic effect of TMZ-Se than TMZ
was observed in human melanoma cell lines 1205LU and
UACC903 (Fig. 2D). These results indicate that the modification
of TMZ structure by incorporation of selenium produces superior
cytotoxicity to TMZ in malignant tumor cells.
TMZ-Se Causes a Greater DNA Damage Response and
a More Severe Impairment of mTOR Signaling
As the cytotoxicity of TMZ is known to be associated with
O
6MeG lesions, which cause DSBs, we compared the level of
phospho-histone H2AX, an indicator of DSBs, in glioma and
melanoma cells treated with TMZ or TMZ-Se. Fig. 3A shows that
the level of phospho-H2AX was remarkably higher in tumor cells
treated with TMZ-Se than in cells treated with TMZ, indicating
that TMZ-Se treatment causes more DSBs than TMZ. As DNA
damage can also cause impairment of mTOR signaling [7] and
TMZ was reported to alter mTOR signaling [8] , we compared
the effects of TMZ-Se and TMZ on activity of the Akt-mTOR-S6
kinase pathway. As shown in Fig. 3B, the greater DNA-damaging
effect of TMZ-Se was also evidenced by the decreases of activity of
Akt, mTOR, and S6 kinase, as demonstrated by decreased levels
of phospho-Akt, phospho-mTOR, and phospho-S6 kinase.
TMZ-Se is More Apoptogenic than TMZ in Tumor Cells
Formation of DNA DSBs can trigger apoptosis; therefore, we
wanted to know whether TMZ-Se would induce greater apoptosis
than TMZ. Flow cytometric analysis of Annexin V staining
showed that TMZ-Se caused 3 , 7-fold more apoptosis than
TMZ in T98G and LN229 cells, and this apoptogenic effect was
dose - dependent (Fig. 4A). Stronger apoptogenic effect of TMZ-
Se was validated by the increased amounts of cleaved caspase-3,
caspase-9 and PARP, and the decreased amounts of the anti-
apoptotic protein, survivin, in the TMZ-Se-treated glioma cells, as
determined by western blot (Fig. 4B). To confirm the role of
apoptosis in the cell killing caused by TMZ-Se, we measured the
cytotoxicity of TMZ-Se in the presence of pan-caspase inhibitor, Z-
VAD. Fig. 4C shows that the presence of Z-VAD significantly
reduced the cytotoxic effect of TMZ-Se in tumor cells, further
supporting the role of apoptosis in the cytotoxicity of TMZ-Se.
The stronger effects of TMZ-Se on apoptosis were also observed
in melanoma cells (Fig. 4D). These results indicate that TMZ-Se
possesses greater apoptosis-promoting activity than TMZ.
TMZ-Se Induces Greater Autophagic Response than TMZ
in Tumor Cells
TMZ has been reported to induce autophagy in tumor cells [9],
and activation of this cellular process can affect sensitivity of tumor
cells to treatments such as chemotherapy and radiotherapy [10].
Thus, we examined and compared autophagenic effects of TMZ-
Se and TMZ in tumor cells. As shown in Fig. 5, in comparison to
TMZ, TMZ-Se induced greater autophagic response, as evi-
denced by elevations of the autophagy marker LC3 II (Fig. 5A),
increases in the GFP-LC3 dots (Fig. 5B), and accumulation of
autophagosomes (Fig. 5C). In the cells treated with TMZ-Se, LC3
II level was further accumulated in the presence of bafilomycinA1,
an inhibitor of autophagosome-lysosome fusion and LC3II
degradation, indicating that autophagic flux was also enhanced
by TMZ-Se (Fig. 5A, right panels). As autophagy can either
promote cell survival or death, we further evaluate the role of
TMZ-Se-activated autophagy in modulating sensitivity of tumor
cells to this new compound. We treated the tumor cells with TMZ-
Se in the absence or presence of the autophagy inhibitors, 3-MA,
bafilomycinA1 or Atg5 siRNA, and then measured cell viability.
Fig. 5D and 5E shows that the cytotoxicity of TMZ-Se against
T98G and LN229 cells was significantly decreased when
autophagy was suppressed, suggesting that activation of autophagy
contributes to the cytocidal action of TMZ-Se.
TMZ-Se Stimulates Calpain-mediated Degradation of
Beclin 1
Despite that treatment with TMZ-Se activated autophagy in
tumor cells (Fig. 5), we unexpectedly found that the expression of
Beclin 1, a key regulator of autophagy, was down-regulated in
tumor cells treated with this compound, as examined by Western
blot (Fig. 6A). With the down-regulation of Beclin 1, there was also
a concomitant decrease in Bcl-2, an anti-apoptotic protein that
interacts with Beclin1 (Fig. 6A). Contrastingly, expression of beclin
1 mRNA was increased following TMZ-Se treatment, as analyzed
by qRT-PCR (Fig. 6B). These results raised the possibility that
down-regulation of Beclin 1 caused by TMZ-Se may result from
enhanced degradation of this protein. To test this hypothesis, we
first determined whether or not the down-regulation of Beclin 1
protein by TMZ-Se could be reversed by MG132, a proteasomal
Figure 1. Chemical structures of TMZ-Se and TMZ.
doi:10.1371/journal.pone.0035104.g001
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TMZ-Se-induced down-regulation of Beclin 1 remained (Fig. 6C),
suggesting that the turnover of Beclin 1 is not mediated via the
ubiquin-proteasome pathway. Notably, the calpain inhibitors,
ALLM and E64D, showed a rescuing effect on Beclin 1 protein in
the cells treated with TMZ-Se (Fig. 6D). These results suggest that
TMZ-Se may have a stimulatory effect on calpain activity, thus
promoting degradation of Beclin 1. We then measured the effects
of calpain on cytotoxic activity of TMZ-Se against tumor cells, and
found that the cytotoxicity of TMZ-Se was significantly decreased
in the presence of ALLM or E64D (Fig. 6E), suggesting that
calpain was involved in the TMZ-Se-induced cell death.
The concurrent activation of autophagy and down-regulation of
Beclin 1 made us query whether TMZ-Se-induced autophagy was
Beclin1-independent. We found that in the cells with silencing of
Beclin 1 expression, TMZ-Se still caused an increase in LC3 II
(Fig. 7A), indicating that dysfunction of Beclin 1 fails to block the
activation of autophagy by TMZ-Se, and the TMZ-Se-activated
autophagy is indeed Beclin 1-independent. Down-regulation of
Beclin 1 appears to contribute to augmentation of apoptosis
induced by TMZ-Se, as silencing of Beclin 1 expression further
increased the amount of cleavage of PARP (Fig.7A). To further
verify the effect of Beclin1 on cell death induced by TMZ-Se, we
compared TMZ-Se toxicity in cells with or without silencing of
Beclin 1 expression. As shown in Fig. 7B, knockdown of Beclin
1enhanced the sensitivity of tumor cells to TMZ-Se. These results
suggest that the degradation of Beclin 1 by calpain plays a role in
promoting apoptosis and enhancing cell death in tumor cells
treated with TMZ-Se.
TMZ-Se Shows a Greater Antitumor Activity than TMZ in
Glioma and Melanoma Xenograft Models
To test and compare the in vivo therapeutic efficacy of TMZ-Se
and TMZ, we determined the anti-tumor effects of these two
compounds in mice bearing either glioma or melanoma xenografts.
In the intracranial LN-229 glioma model, tumor-bearing mice
Figure 2. Comparison of cytotoxicity of TMZ-Se and TMZ in glioma and melanoma cell lines. (A) Human glioma cell lines T98G, LN229,
U251 and U87MG were treated with a series concentration of TMZ or TMZ-Se for 48 h, and cell viability was measured by MTT assay. (B) T98G cells
were treated with TMZ or TMZ-Se for 3 days, and then were incubated for 12 days at 37uC in a humidified atmosphere containing 5% CO2/95% air. At
the end of incubation, the cells were stained with 1% methylene blue in 50% methanol for 30 min, washed with water, and colonies counted. (C)
TMZ-resistant glioma cell line CCF-STTG was treated with TMZ or TMZ-Se for 72 h, and cell viability was measured by MTT assay. (D) Human
melanoma cell lines 1205LU and UACC903 were treated with a series concentration of TMZ or TMZ-Se for 48 h, and cell viability was measured by
MTT assay.
doi:10.1371/journal.pone.0035104.g002
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and smaller tumor masses than those treated with same dose of
TMZ,asevidencedbyhistologicexaminationsofthebraintissueson
day 7 and day 21 following tumor inoculations (Fig. 8A). In
a melanoma xenograft model, TMZ-Se also showed a significantly
stronger tumor-inhibiting activity as compared to TMZ without
observable systemic toxicity (Fig. 8C). On average, the tumor
volumeis,30 mm
3lowerinTMZ-SegroupthaninTMZgroup(p-
value=0.0003). These results indicate that TMZ-Se also had
a greater antitumor activity than TMZ in vivo, and demonstrate the
potential of TMZ-Se as a more effective anticancer agent than
TMZ.
Discussion
Several types of malignant tumors, such as glioblastoma
multiforme and melanoma, are notoriously resistant to conven-
tional chemotherapy. Even for TMZ, the frontline drug for
treatment of glioblastoma multiforme and metastatic melanoma,
its therapeutic outcomes are often disappointing. In the current
study, we show that TMZ-Se, a new TMZ analog developed and
synthesized by our group, is superior to TMZ in inhibiting viability
of glioma and melanoma cells (Fig. 2), and in suppressing growth
of tumor xenograts in animal models (Fig. 8). Noteworthily, TMZ-
Se also showed efficacy against TMZ-resistant tumor cells (Fig. 2).
The cytotoxic effect of methylating agents is believed to result from
formation of O
6-MeG, which causes DNA DSBs that act as
a trigger of apoptotic cell death [2]. Also, a number of studies have
shown that selenium has a potent anti-cancer activity that
correlates with its apoptosis - inducing effects [11,12]. These
observations have recently led to development of several
organoselenium small molecule compounds, both in our labora-
tories and elsewhere, which showed promising anti-tuomr
properties [13,14,15,16,17,18,19]. The introduction of selenium
into TMZ structure was particularly challenging because the
changes in structure should not compromise its ability to cross the
blood brain barrier (BBB). Therefore, we designed TMZ-Se by
extending the amide functionality in TMZ so as not to disturb the
ring involved in degradation to active metabolites and responsible
for 100% bioavailability and apparently the BBB crossing ability of
TMZ [20]. The -SeCN group was used as carrier of selenium to
generate a second active moiety into TMZ structure since it is
known to be efficiently metabolized to a selenol (-SeH) in-
termediate that is responsible for the redox cycling and anticancer
properties of selenium. Our results suggest that TMZ-Se acts by
retaining the properties of both TMZ and Se. The efficient
reduction in brain tumor xenografts clearly indicates that TMZ-Se
Figure 3. Effects of TMZ-Se and TMZ on phosphorylation of H2AX, and on activity of Akt-mTOR-S6K pathway. (A) T98G, LN229,
1205LU and UACC903 cells were treated with 100 mM or 200 mM of TMZ or TMZ-Se for 48h, and the level of phospho-H2AX was measured by
Western blot. Tubulin was used as a loading control. (B) LN229 and T98G cells were treated with TMZ or TMZ-Se for 48 h, and the levels of p-Akt, Akt,
p-mTOR, mTOR, p-S6K, and S6K were measured by Western blot analysis. Tubulin was used as a loading control.
doi:10.1371/journal.pone.0035104.g003
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TMZ-Se metabolizes similar to TMZ, leading to active inter-
mediates by cleaving the tetrazene ring, which apparently is
responsible for its crossing through the BBB. In addition, the
enhanced cytotoxicity of TMZ-Se as compared to TMZ indicates
the expected usual functioning of -SeCN group, which would
cleave to generate a free selenol (-SeH) thus adding the redox
cycling properties of Se and enhancing selective cytotoxicity to
tumor cells.
We demonstrated that rational introduction of selenium into
TMZ greatly increased the inducing effect on DNA DSB (Fig. 3)
and on apoptosis (Fig. 4). TMZ-induced apoptosis is a late
response that needs at least two cell cycles after treatment [21].
For instance, apoptosis in gliomas is only visible 4–6 days
following TMZ treatment [9], and TMZ - treated melanoma
cells start to undergo apoptosis 72 h later [22]. It appears that
TMZ-Se not only possesses stronger apoptosis - inducing activity
but also triggers cell death more rapidly than TMZ, as at 48 h
post-treatment, more marked apoptosis were observed in tumor
cells treated with TMZ-Se than those treated with TMZ (Fig. 4).
Autophagy is a catabolic process by which damaged organelles
and proteins are sequestered into autophagosome and sub-
sequently degraded through fusion with lysosomes. It was found
in both glioma cells and tissues that TMZ treatment caused
activation of autophagy [9] [23], but the precise roles of autophagy
in determining the efficacy of this drug remains uncertain. We
found that our new compound, TMZ-Se, induced stronger
autophagic response than TMZ in glioma cells (Fig. 5). There
has long been debate over whether autophagy is cell-killing or cell-
protective in cancers. Autophagy was originally recognized as
a cell-protective mechanism under various stressful conditions, but
later was also found to play a death-promoting role, causing
autophagic cell death [24]. Here, we demonstrated that inhibition
of autophagy decreased the efficacy of TMZ-Se against glioma
(Fig. 5D and E), indicating that autophagy plays a pro-death role
and contributes to the antitumor effects of TMZ-Se. Interestingly,
we found that Beclin 1, a critical regulator of autophagy, was
Figure 4. TMZ-Se is more apoptogenic than TMZ in tumor cells. (A) LN229 and T98G cells were treated with 100 mM or 200 mM of TMZ or
TMZ-Se for 48 h, and apoptosis was examined by flow cytometric analysis of Annexin V and 7-AAD staining. (B) LN229 and T98G cells were treated
with TMZ or TMZ-Se for 48h, and the levels of caspse-9, caspase-3, PARP and survivin were measured by Western blot analysis. Tubulin was used as
a loading control. (C) LN229 and T98G cells were treated with TMZ-Se for 48h in the absence or presence of Z-VAD, and cell viability was measured by
MTT assay. (D) 1205LU and UACC cells were treated with TMZ or TMZ-Se for 48h, and the levels of PARP and survivin were measured by Western blot.
Tubulin was used as a loading control. *p , 0.05; **p , 0.01.
doi:10.1371/journal.pone.0035104.g004
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calpain, a Ca
2+-dependent protease involved in control of cell
proliferation and apoptosis, blocked the degradation of Beclin1
induced by TMZ-Se (Fig. 6D). Calpain-triggered degradation of
Beclin 1 has been reported by Yoo BH et al. who demonstrated
that calpain activity is required for Ras-dependent down-
regulation of Beclin-1 [25]. Additionally, we found that the
decrease in Beclin 1 protein was not accompanied by a reduction
in LC3 but resulted in an increase in PARP (Fig. 7A), suggesting
that TMZ-Se triggers a non-canonical, Beclin 1-independent
autophagy, and the calpain-mediated degradation of Beclin 1
promotes the apoptotic response to this agent. It was previously
reported that Beclin 1 participates in inhibition of apoptosis, and
that silencing of Beclin 1 expression augments the mitochondrial
permeabilization and apoptosis induced by Fas stimulation or
doxorubicin treatment in tumor cells [26]. The previous studies
also demonstrated that the interaction of Beclin 1 with either Bcl-2
or Bcl-XL is essential for the anti-apoptotic effects of Beclin 1 [27].
We have reported that inhibition of Beclin 1 increased the caspase
activities in glioma cells treated with TRAIL via reducing survivin
level [28]. Here, we observed a decrease in Bcl-2 expression in
glioma cells subjected to TMZ-Se treatment, indicating that the
decrease of Beclin 1 leads to the dissociation of Beclin1 with Bcl-2,
thereby promoting the degradation of Bcl-2 and causing apoptosis.
All of these results suggest that there might be new mechanisms of
action involved in the antitumor effects of TMZ-se.
TMZ-Se also showed a stronger antitumor activity in both the
glioma and melanoma mouse models (Fig. 8), suggesting that
TMZ selenium derivatives may hold promise for further de-
veloping as novel chemotherapeutic agents. We are planning
further pre-clinical studies including pharmacokinetic comparisons
to determine whether or not TMZ-Se warrants clinical trials in the
hope of developing it to a useful and effective anticancer agent.
Taken together, by introducing selenium into TMZ, we have
developed a novel TMZ analog that demonstrates superior anti-
tumor activity against glioma and melanoma both in vitro and in
vivo. This also suggests that by modifying the amide function, we
were able to retain the BBB-penetrating capability of Se-TMZ
while enhancing its tumor-inhibitory property. We believe that
appropriately incorporating selenium into certain conventional
Figure 5. TMZ-Se triggers a greater autophagic response than TMZ, and inhibition of autophagy decreases the efficacy of TMZ-Se
against glioma cells. (A) Left panels: LN229 and T98G cells were treated with TMZ or TMZ-Se for 48 h, and the level of LC3 was measured by
Western blot analysis. Tubulin was used as a loading control. Right panels: LN229 and T98G cells were treated with TMZ-Se for 48 h in the presence or
absence of bafilomycinA1, and the level of LC3 was measured by Western blot analysis. Tubulin was used as a loading control. (B) LN229 and T98G
cells were transfected with a GFP-LC3 plasmid, followed by treatment with TMZ-Se for 48h. At the end of treatment, the cells were observed under
fluorescence microscope. (C) T98G cells treated with TMZ-Se or vehicle were harvested by trypsinization, fixed and embedded in spur resin. Ninety
nm thin sections were cut and examined at 80 Kv with a JEOL 1200EX transmission electron microscope. (D) LN229 and T98G cells were treated with
TMZ-Se for 48h in the absence or presence of 3-MA or bafilomycinA1, and cell viability was measured by MTT assay. (E) LN229 and T98G cells were
transfected with an Atg5-targeted siRNA, and then treated with TMZ-Se for 48h. Cell viability was measured by MTT assay. *p , 0.05; **p , 0.01.
doi:10.1371/journal.pone.0035104.g005
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a new strategy of drug development that is worth further
investigation.
Materials and Methods
Synthesis of TMZ-Se
The 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-
triene-9-(N-selenocyanatoethyl) carboxamide (TMZ-Se) was syn-
thesized starting from TMZ according to our recently developed
method (manuscript under preparation). Briefly, the amide
functionality in TMZ was first converted to an acid chloride by
treating TMZ with sodium nitrite followed by hydrolysis to give
the corresponding acid, and subsequently treating with thionyl
chloride. Treatment of acid chloride with aminoethyl bromide
gave bromo intermediate that was finally converted to the desired
TMZ-Se by a reaction with potassium selenocyanide. The
compound was characterized by NMR and MS and its purity
(.99%) was determined by HPLC.
Cell Lines and Culture
The human glioblastoma cell lines, T98G, LN-229, U251 and
U87MG, and human melanoma cell lines 1205LU and UACC
were purchased from American Type Culture Collection (ATCC).
T98G cells were cultured in Ham’s F-10: DMEM (10:1) medium,
and LN-229, U251, U87MG, 1205LU and UACC cells were
cultured in DMEM medium. These media were supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, and
100 mg/mL streptomycin. Cells were maintained at 37uCi n
a humidified atmosphere containing 5% CO2/95% air. All
cultures were monitored routinely and found to be free of
contamination by mycoplasma or fungi. All cell lines were
discarded after three months and new lines propagated from
frozen stocks.
Reagents and Antibodies
TMZ was purchased from Tocris Bioscience (Ellisville,
Missouri). Anti-phospho-H2AX antibody was purchased from
upstate-cell signaling solutions (Lake placid, New York). 3-(4, 5-
Figure 6. TMZ-Se induces calpain-mediated degradation of Beclin 1. LN229 and T98G cells were treated with 100 or 200 mM of TMZ or TMZ-
Se for 48h, (A) the levels of Beclin 1 and Bcl-2 were measured by Western blot. Tubulin was used as a loading control; (B) the expression of beclin1
mRNA was measured by qRT-PCR. (C) LN229 and T98G cells were treated with 100 or 200 mM of TMZ-Se for 48h in the presence or absence of 10mM
of MG132, and the level of Beclin 1 were measured by Western blot. Tubulin was used as a loading control. (D) LN229 and T98G cells were treated
with TMZ-Se for 48h in the presence or absence of 20mM ALLM (left panel)o r1 0 mg/ml E64D (right panel), and the level of Beclin1 was measured by
Western blot. Tubulin was used as a loading control. (E) LN229 and T98G cells were treated with TMZ-Se for 48h in the presence or absence of 20mM
ALLM or 10mg/ml E64D, and cell viability was measured by MTT assay. **p , 0.01.
doi:10.1371/journal.pone.0035104.g006
Antitumor Effects of Temozolomide Derivative
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35104dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3-
methyladenosine (3-MA), MG132, ALLM, bafilomycin A1 and Z-
VAD were purchased from Sigma (Denver, Colorado). Anti-
caspase-3, anti-caspase-9, anti-PARP, anti-survivin, anti–LC-3,
anti–a-tubulin, anti -Akt, anti-phospho-Akt (Ser 473), anti–
phospho-mTOR (Ser 2448), anti–mTOR, anti–phospho-S6
kinase (Ser371), anti–S6 kinase, anti-Beclin1 antibodies were
purchased from Cell Signaling Technologies (Boston, Massachu-
setts). All cell culture media and other reagents were purchased
from Invitrogen (Carlsbad, California). Western blot reagents
were obtained from Pierce Biotechnology (Rockford, Illinois) .
Measurement of Autophagy
Autophagy was monitored using the following methods: 1)
Western blot analysis of LC3; 2) microscopic observation of GFP-
LC3 puncta; 3) electron microscopic examination of double or
multi-membrane vacuoles in the cytoplasm.
Western Blot
Cells were lysed in M-PER mammalian protein extraction
reagent (Thermo Scientific, Rochester, New York) supplemented
with a protease inhibitor cocktail (Roche, South San Francisco,
California) at room temperature for 5 minutes followed by
centrifugation at 14,0006g for 10 minutes. Protein Concentra-
tions of the cell lysates were measured using the Bio-Rad DC assay
(Bio-Rad, Hercules, California). Proteins (20–40 mg) were resolved
on SDS-PAGE and transferred to PVDF membrane (Bio-Rad,
Hercules, California). The blots were incubated with indicated
antibodies in 3% BSA/TBST at 4uC for overnight followed by
incubation with secondary antibodies at room temperature for 1 h.
The protein signals were detected by ECL method.
Apoptosis Assays
Apoptosis was determined by flow cytometric analysis of
Annexin V and 7-AAD staining. Briefly, 100 ml Guava Nexin
reagent (Millipore, Billerica, Massachusetts) was added to 1610
5
cells (in 100 ml) and the cells were incubated with the reagent for
20 min at room temperature in the dark. At the end of incubation,
the cells were analyzed by a Guava EasyCyte
TMPlus Flow
Cytometry System (Millipore, Billerica, Massachusetts).
Cellular Viability Assay
Cell viability was measured by MTT assay. Briefly, cells were
plated at 5610
3 cells per well in 96-well tissue culture plates
and incubated at 37uC in a humidified atmosphere containing
5% CO2/95% air. The formazan product, formed after 4h
incubation with MTT, was dissolved in DMSO and read at
570 nm on a Victor3 Multi Label plate reader (PerkinElmer,
San Jose, California).
Figure 7. TMZ-Se induces calpain-mediated degradation of Beclin 1. (A) LN229 and T98G cells were transfected with Beclin1siRNA followed
by TMZ-Se treatment, and the levels of LC3, Beclin 1 and PARP were examined by Western blot. Tubulin was used as a loading control. (B) LN229 and
T98G cells were transfected with a Beclin 1-targeted siRNA, followed by treatment with TMZ-Se for 48h. Cell viability was measured by MTT assay.
*p , 0.05; **p , 0.01.
doi:10.1371/journal.pone.0035104.g007
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Tumor cells were plated in 35-mm cell culture dishes (200 cells/
dish) and treated with drug for 3 days. Then, the cells were
incubated at 37uC in a humidified atmosphere containing 5%
CO2/95% air for 12days. At the end of the incubation period,
cells were stained with 1% methylene blue in 50% methanol for
30 min, washed with water, and colonies counted.
Real Time-PCR
Total RNAs were isolated from the treated cells using the Trizol
isolation reagent (Roche, South San Francisco, California)
according to the manufacturer’s instruction. The concentrations
of total RNAs were measured using a NanoDrop (Thermo
Scientific, Rochester, New York). First-strand cDNA was
synthesized using Omniscript reverse transcription kit (Qiagen,
Valencia, California) with random primers, according to the
manufacturer’s instruction. Real time PCR was performed on
a Stratagene Mx3005P using Brilliant II SYBR Green QPCR
master mix (Stratagene, La Jolla, California) and following
primer sets: beclin1,5 9-CAA GAT CCT GGA CCG TGT CA-
39 (forward) and 59-TGG CAC TTT CTG TGG ACA TCA-39
(reverse); b-actin,5 9-GCC AAC ACA GTG CTG TCT GG-39
(forward) and 59-GCT CAG GAG GAG CAA TGA TCT TG-
39 (reverse). After 40 cycles, data were collected and analyzed
by MxPro software (Stratagene, La Jolla, California).
Animal Study
Orthotopic glioblastoma mouse model: Six-week old male BALB/c
nude mice were used for intracerebral injections of glioma cells.
Mice were anesthetized with chloralic hydras (4%, 0.2ml/100g,
i.p.), and then were inoculated with LN229 cells (160
5)i n1 5mlo f
DMEM in the brains at 4.3 mm depth. Three days after tumor
implantation, mice were randomly divided into three groups (15
mice/group). Treatment was initiated on day 4. TMZ-Se (15 mg/
kg), TMZ (15 mg/kg) or vehicle were given p.o. daily for 2 weeks.
Figure 8. Effects of TMZ-Se and TMZ on tumor growth in mouse glioma and melanoma xenograft models. (A and B) The human
glioma cells LN229 (1610
5 cells in 15 ml of DMEM medium) were injected into the brains of 6-week-old male BALB/c nude mice at 4 mm depth under
anesthesia with chloralic hydras (4%, 2ml/kg, ip). Three days after tumor cell implantation, mice were randomly divided into three groups (15 mice/
group). Treatments were begun on day 4. TMZ-SE (15 mg/kg), TMZ (15 mg/kg) or vehicle (10% DMSO in saline) was given p.o. daily for 2 weeks. (A)
At day 7 and day 21 after tumor cell implantation, the mice were euthanized, and the brains were fixed in 10% buffered formalin, embedded in
paraffin, and then stained with hematoxillin-eosin (H&E). The images shown are the representative of 5 mice from each group; (B) The kaplan-Meier
survival curves, n=10; (C) Nude mice (swiss
nu/nu) were inoculated s.c. with UACC903 human melanoma cells (1610
6 cells/100 ml/mouse). When the
tumors reached 50,100 mm
3 in volume, TMZ or TMZ-Se (15 mg/kg) was administered i.p. on days 1, 3, 5, 7 and 9. Tumor sizes and body weight of
the animals were measured every other day. The differences between treatments were analyzed using a two-sample t-test. The survival curves of the
tumor - bearing mice subjected to different treatments were estimated using Kaplan-Meier method and compared by log-rank statistic analysis.
doi:10.1371/journal.pone.0035104.g008
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experiment. Five mice of each group were killed at day 7 and 21
following tumor inoculation. Brains were fixed in 10% buffered
formalin and embedded in paraffin, and then stained with
hematoxillin-eosin (H&E). Melanoma mouse model: Nude mice
(swiss
nu/nu) were inoculated s.c. with UACC903 melanoma cells
(1610
6 cells/100 ml/mouse). When the tumors reached
50,100 mm
3 in volume, the mice were treated i.p. with TMZ
or TMZ-Se (15 mg/kg) on days 1, 3, 5, 7 and 9. Tumor sizes and
body weight of the animals were measured every other day. Mice
were housed in an animal facility and were maintained in
a temperature-controlled and light-controlled environment. The
animal experiments were approved by the Institutional Animal
Care and Use Committee of Penn State College of Medicine. The
differences between treatments were analyzed using a two-sample
t-test. The survival curves of the tumor - bearing mice subjected to
different treatments were estimated using Kaplan-Meier method
and compared by log-rank statistic analysis.
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